Merck teams up with cancer startup Foghorn in $425M deal

Two years after its official launch, next-gen cancer biotech Foghorn Therapeutics has nabbed a biobucks deal with Big Pharma Merck.

The Cambridge, Massachusetts-based biotech launched in March 2018 aiming to develop drugs for cancer as well as other serious diseases based on insights into the chromatin regulatory system.